Cwm, LLC Intellia Therapeutics, Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Cwm, LLC holds 953 shares of NTLA stock, worth $13,437. This represents 0.0% of its overall portfolio holdings.

Number of Shares

953

Previous 740 28.78%

Holding current value

$13,437

Previous $17,000 17.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$19.72 - $27.36 $4,200 - $5,827	213 Added 28.78%	953 $20,000
Q2 2024 Jul 09, 2024	SELL	$20.02 - $27.22 $1,721 - $2,340	-86 Reduced 10.41%	740 $17,000
Q1 2024 Apr 05, 2024	SELL	$23.82 - $32.8 $5,550 - $7,642	-233 Reduced 22.0%	826 $23,000
Q4 2023 Feb 01, 2024	BUY	$23.16 - $32.34 $7,804 - $10,898	337 Added 46.68%	1,059 $32,000
Q3 2023 Oct 11, 2023	BUY	$31.62 - $45.78 $1,391 - $2,014	44 Added 6.49%	722 $23,000
Q2 2023 Aug 03, 2023	SELL	$34.58 - $46.03 $2,247 - $2,991	-65 Reduced 8.75%	678 $28,000
Q1 2023 Apr 28, 2023	BUY	$33.3 - $44.82 $865 - $1,165	26 Added 3.63%	743 $28,000
Q4 2022 Feb 01, 2023	BUY	$33.21 - $62.69 $22,715 - $42,879	684 Added 2072.73%	717 $25,000
Q3 2022 Oct 27, 2022	SELL	$53.92 - $71.7 $5,445 - $7,241	-101 Reduced 75.37%	33 $2,000
Q2 2022 Jul 28, 2022	SELL	$38.49 - $76.21 $2,347 - $4,648	-61 Reduced 31.28%	134 $7,000
Q1 2022 Apr 21, 2022	BUY	$58.27 - $118.99 $10,954 - $22,370	188 Added 2685.71%	195 $14,000
Q4 2021 Jan 31, 2022	BUY	$100.76 - $138.36 $705 - $968	7 New	7 $1,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.07B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account